Cancer BiologybioRxiv
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
L. Brunet, D. Alexandre, J. Lee…·L. Grumolato
This study shows that sorafenib can prolong lung cancer response to EGFR inhibitors by targeting resistant cells' selective advantage.
DOI 10.1038/s41467-025-61788-w